This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioPharm America
2 days in-person. 2 days virtually.
September 28–29, 2022 | Boston, USAOctober 4–5, 2022 | Virtual

Logomix Inc


Logomix’s core competence is Geno-Writing™ platform: a collective knowledge and technologies that enable Mb-scale design and re-construction of human and the other mammalian genomes to create newly functionalized cells. Currently, Logomix provides human model cells of diseases that are caused (or are hypothesized to be caused) by larger chromosomal structural modification than simple indels, such as triplet repeat diseases and pathogenic CNVs.